Remission in Adults With Severe Asthma in Thailand
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThammasat University
About this trial
The goal of this observational study is to determine the prevalence of remission among adults with severe asthma, as well as the factors associated with remission in Thailand.
The main question the study aims to answer is:
What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete questionnaires on asthma symptoms and undergo pulmonary function testing and a blood test once.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
severe asthma
age 18 years or older
Disqualifiers
inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test
Trial population
Thai patients aged 18 years or older with severe asthma are included in the study
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires
Other interventionGINA and ACT are questionnaires used to assess the level of asthma control.
Spirometry
Diagnostic testSpirometry is a tool used to assess pulmonary function.
Fractional exhaled nitric oxide (FeNO) test
Diagnostic testFeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.
Blood eosinophil count (BEC)
Diagnostic testBEC is a tool used to assess eosinophilic inflammation and asthma remission.
Treatment groups
230 Participants
are divided into 1 treatment groupGroup A: Severe asthma4 interventions
Trial outcomes
Primary outcomes
1
Prevalence rate of severe asthma remission
Prevalence rate of remission in adults with severe asthma
Time frame
The beginning of the studySecondary outcomes
1
Association of clinical characteristics with severe asthma remission
The association between severe asthma remission and the following variables will be evaluated: 1. Asthma symptom control; Asthma Control Test (ACT) score (range 5-25) 2. Exacerbation history; Number of asthma exacerbations requiring systemic corticosteroids in the previous 12 months 3. Oral corticosteroid use; Daily oral corticosteroid use (yes/no) and cumulative dose (mg/year) 4. Asthma duration; Years since asthma diagnosis
Time frame
The beginning of the study2
Association of lung function with severe asthma remission
The association between severe asthma remission (binary outcome: remission vs. non-remission) and pulmonary function assessed using spirometry (FEV1 % predicted and FEV1/FVC ratio).
Time frame
The beginning of the study3
Association of inflammatory biomarkers with severe asthma remission
The association between severe asthma remission (binary outcome: remission vs. non-remission) and inflammatory biomarkers assessed using blood eosinophil count (cells/µL) and fractional exhaled nitric oxide (FeNO) (parts per billion, ppb).
Time frame
The beginning of the studySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov